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Human tumors consist of heterogeneous populations
with different phenotypic characteristics, and these sub-
populations can often be distinguished by different sur-
face marker expression. In head and neck squamous cell
carcinoma (HNSCC), CD44 has been identified to be a
marker of a subpopulation, containing the tumor-initiat-
ing cells (or cancer stem cells), which are capable of
self-renewal and differentiation into cells lacking this
capacity. Significant evidence indicates that these tumor-
initiating cells have an immune suppressive phenotype,
allowing them to evade the antitumor host immune
response, leading some to hypothesize that these cells
may contribute to long-term tumor dormancy. In this
study, we profiled 21 primary human HNSCC tumors
and/or patient-derived xenografts for CD44 expression
and PD-L1 (B7-H1) expression by flow cytometry and
quantitative RT-PCR. The tumors were categorized into
PD-L1-negative and PD-L1-positive tumors. In the PD-
L1-positive tumors, we found elevated expression of
PD-L1 on CD44+ cells, both at the protein level by flow
cytometry and at the transcript level by qRT-PCR. Inter-
estingly, treatment of the tumor cells with recombinant
IFN-g resulted in preferential up-regulation of PD-L1 on
CD44+ cells (as compared to the CD44- population) in
both PD-L1-negative and PD-L1-positive tumors. To
assess the functional significance of the preferential
PD-L1 expression on the CD44+ tumor cells, autologous
tumor-infiltrating lymphocytes (TILs) were cultured
from the primary tumors. By ELISA, autologous co-cultures
of CD8+ TILs with sorted subsets of tumor cells showed
higher secretion of IFN-g when incubated with CD44- cells
compared to CD44+ cells, suggesting that the CD44+
cells are more immunosuppressive. Blocking the TILs with
anti-PD-L1 and anti-PD-1 antibodies partially restored
IFN-g secretion by the TILs incubated with the CD44+
cells, indicating that part of the immunosuppressive proper-
ties of CD44+ cells is mediated by the PD-L1-PD-1 signal-
ing pathway. Our results indicate that the preferential
PD-L1 expression on tumor-initiating cells may function as
one of multiple mechanisms by which long-term tumor-
initiating progenitor cells evade the immune response and
provide rationale for targeting the PD-1 axis in the adjuvant
therapy setting.
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